{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:57:14Z","timestamp":1788487034708,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Foundation for Science and Technology (FCT), Portugal"},{"name":"FEDER\/COMPETE","award":["UID\/QUI\/00081"],"award-info":[{"award-number":["UID\/QUI\/00081"]}]},{"name":"FEDER\/COMPETE","award":["NORTE-01-0145-FEDER-000028"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000028"]}]},{"name":"FEDER\/COMPETE","award":["POCI-01-0145-FEDER-029164"],"award-info":[{"award-number":["POCI-01-0145-FEDER-029164"]}]},{"name":"NSERC-Discovery","award":["RGPIN: 03830-2014"],"award-info":[{"award-number":["RGPIN: 03830-2014"]}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation (CFI-JELF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012171","name":"Ontario Research Fund (ORF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Early Researcher Award (ERA), Ministry of Research and Innovation, Government of Ontario, Canada (PPNR)"},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["SFRH\/BPD\/114945\/2016"],"award-info":[{"award-number":["SFRH\/BPD\/114945\/2016"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FEDER\/COMPETE"},{"DOI":"10.13039\/501100003248","name":"Ontario Mental Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ejmech.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T11:49:35Z","timestamp":1549280975000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Repurposing nitrocatechols: 5-Nitro-\u03b1-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6"],"prefix":"10.1016","volume":"167","author":[{"given":"Tiago","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Shakeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5703-8251","authenticated-orcid":false,"given":"Praveen P.N.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcio","family":"Soares da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Remi\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1050-2402","authenticated-orcid":false,"given":"Fernanda","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.02.006_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.1.110304.100113","article-title":"Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications","volume":"1","author":"Skovronsky","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ejmech.2019.02.006_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrd3050","article-title":"Protein aggregation diseases: pathogenicity and therapeutic perspectives","volume":"9","author":"Aguzzi","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.02.006_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrn2967","article-title":"Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease","volume":"12","author":"Ittner","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejmech.2019.02.006_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2019.02.006_bib5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev-pharmtox-011613-135932","article-title":"Emerging therapeutics for Alzheimer's disease","volume":"54","author":"Chiang","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2019.02.006_bib6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jnc.13018","article-title":"A\u00a0novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in\u00a0vitro","volume":"133","author":"Coutadeur","year":"2015","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1021\/cn5001815","article-title":"First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease","volume":"5","author":"Mariano","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2019.02.006_bib8","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1002\/anie.201208290","article-title":"Mechanistic basis of phenothiazine-driven inhibition of tau aggregation","volume":"52","author":"Akoury","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2019.02.006_bib9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.expneurol.2009.08.031","article-title":"Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors","volume":"223","author":"Brunden","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2019.02.006_bib10","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1074\/jbc.M114.616029","article-title":"Cellular models of Aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of alzheimer disease","volume":"290","author":"Harrington","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib11","doi-asserted-by":"crossref","first-page":"e0117511","DOI":"10.1371\/journal.pone.0117511","article-title":"PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in\u00a0vivo","volume":"10","author":"Okuda","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.02.006_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/acschemneuro.5b00013","article-title":"Azaphilones inhibit tau aggregation and dissolve tau aggregates in\u00a0vitro","volume":"6","author":"Paranjape","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2019.02.006_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejmech.2014.07.095","article-title":"Development of dual targeting inhibitors against aggregations of amyloid-beta and tau protein","volume":"85","author":"Fuse","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib14","doi-asserted-by":"crossref","unstructured":"Mohamed, T., Hoang, T., Jelokhani-Niaraki, M., Rao, P.P. Tau-derived-hexapeptide 306VQIVYK311 aggregation inhibitors: nitrocatechol moiety as a pharmacophore in drug design. ACS Chem. Neurosci. 4, 1559-1570.","DOI":"10.1021\/cn400151a"},{"key":"10.1016\/j.ejmech.2019.02.006_bib15","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M109.080390","article-title":"Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity","volume":"285","author":"Di Giovanni","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fnagi.2014.00197","article-title":"Structure activity relationship of phenolic acid inhibitors of alpha-synuclein fibril formation and toxicity","volume":"6","author":"Ardah","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2019.02.006_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2174\/138955708784223512","article-title":"Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease","volume":"8","author":"Bastianetto","year":"2008","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13506120601116674","article-title":"The molecular mechanisms of the anti-amyloid effects of phenols","volume":"14","author":"Shoval","year":"2007","journal-title":"Amyloid"},{"key":"10.1016\/j.ejmech.2019.02.006_bib19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.neuroscience.2008.06.056","article-title":"Caffeic acid phenethyl ester prevents cerebellar granule neurons (CGNs) against glutamate-induced neurotoxicity","volume":"155","author":"Wei","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2019.02.006_bib20","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1039\/C4CS00138A","article-title":"Biological metals and metal-targeting compounds in major neurodegenerative diseases","volume":"43","author":"Barnham","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2019.02.006_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-510X(98)00092-6","article-title":"Copper, iron and zinc in Alzheimer's disease senile plaques","volume":"58","author":"Lovell","year":"1998","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.ejmech.2019.02.006_bib22","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/j.1471-4159.2009.05901.x","article-title":"Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD","volume":"108","author":"Kitazawa","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ab.2013.07.015","article-title":"Probing copper\/tau protein interactions electrochemically","volume":"442","author":"Martic","year":"2013","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib24","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejmech.2019.02.006_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejmech.2012.12.049","article-title":"Exploring nature profits: development of novel and potent lipophilic antioxidants based on galloyl-cinnamic hybrids","volume":"62","author":"Teixeira","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib26","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1021\/acs.jmedchem.6b00666","article-title":"Development of blood-brain barrier permeable nitrocatechol-based catechol O-methyltransferase inhibitors with reduced potential for hepatotoxicity","volume":"59","author":"Silva","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib27","doi-asserted-by":"crossref","first-page":"e1001080","DOI":"10.1371\/journal.pbio.1001080","article-title":"Towards a pharmacophore model for amyloid","volume":"9","author":"Landau","year":"2011","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2019.02.006_bib28","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1016\/j.bmc.2015.04.009","article-title":"Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease","volume":"23","author":"Xie","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0003-2697(81)90184-6","article-title":"A\u00a0continuous spectrophotometric assay for arylsulfatase activity, dependent on the formation of complexes between cupric ions and nitrocatechols","volume":"118","author":"Clark","year":"1981","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2019.02.006_bib30","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1021\/ja110545h","article-title":"Macrocyclic \u03b2-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide","volume":"133","author":"Zheng","year":"2011","journal-title":"J.\u00a0Am. Chem. Soc."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419301163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419301163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T17:37:22Z","timestamp":1565199442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419301163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":30,"alternative-id":["S0223523419301163"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.006","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing nitrocatechols: 5-Nitro-\u03b1-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}